Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview

被引：51

作者：

Ali, Manasik Gumah ^{[1
]}

Zhang, Zhening ^{[1
]}

Gao, Qi ^{[1
]}

Pan, Mingzhu ^{[1
]}

Rowan, Edward G. ^{[2
]}

Zhang, Juan ^{[1
]}

机构：

[1] China Pharmaceut Univ, Antibody Engn Lab, Sch Life Sci & Technol, Nanjing, Peoples R China

[2] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland

来源：

IMMUNOLOGIC RESEARCH | 2020年 / 68卷 / 06期

基金：

中国国家自然科学基金;

关键词：

Humoral immune response; Epitope; Neutralizing antibodies; Monoclonal; Polyclonal; Phage display; Glycoprotein; HUMAN MONOCLONAL-ANTIBODIES; POSTEXPOSURE EFFICACY; POLYCLONAL ANTIBODIES; EFFICIENT GENERATION; FUNCTIONAL RECEPTOR; EFFECTOR FUNCTIONS; FUSION PROTEINS; HIGHLY POTENT; SPIKE PROTEIN; B-CELLS;

D O I：

10.1007/s12026-020-09159-z

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antibodies are considered as an excellent foundation to neutralize pathogens and as highly specific therapeutic agents. Antibodies are generated in response to a vaccine but little use as immunotherapy to combat virus infections. A new generation of broadly cross-reactive and highly potent antibodies has led to a unique chance for them to be used as a medical intervention. Neutralizing antibodies (monoclonal and polyclonal antibodies) are desirable for pharmaceutical products because of their ability to target specific epitopes with their variable domains by precise neutralization mechanisms. The isolation of neutralizing antiviral antibodies has been achieved by Phage displayed antibody libraries, transgenic mice, B cell approaches, and hybridoma technology. Antibody engineering technologies have led to efficacy improvements, to further boost antibody in vivo activities. "Although neutralizing antiviral antibodies have some limitations that hinder their full development as therapeutic agents, the potential for prevention and treatment of infections, including a range of viruses (HIV, Ebola, MERS-COV, CHIKV, SARS-CoV, and SARS-CoV2), are being actively pursued in human clinical trials."

引用

页码：325 / 339

页数：15

共 141 条

[1] Opportunities to Exploit Non-Neutralizing HIV-Specific Antibody Activity [J].

Ackerman, Margaret E. ;

Alter, Galit .

CURRENT HIV RESEARCH, 2013, 11 (05) :365-377

[2] Immune history profoundly affects broadly protective B cell responses to influenza [J].

Andrews, Sarah F. ;

Huang, Yunping ;

Kaur, Kaval ;

Popova, Lyubov I. ;

Ho, Irvin Y. ;

Pauli, Noel T. ;

Dunand, Carole J. Henry ;

Taylor, William M. ;

Lim, Samuel ;

Huang, Min ;

Qu, Xinyan ;

Lee, Jane-Hwei ;

Salgado-Ferrer, Marlene ;

Krammer, Florian ;

Palese, Peter ;

Wrammert, Jens ;

Ahmed, Rafi ;

Wilson, Patrick C. .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (316)

[3]

Behring EV., 1890, DEV DIPHTHERIA IMMUN

[4] Maintenance of serological memory by polyclonal activation of human memory B cells [J].

Bernasconi, NL ;

Traggiai, E ;

Lanzavecchia, A .

SCIENCE, 2002, 298 (5601) :2199-2202

[5] Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak [J].

Bornholdt, Zachary A. ;

Turner, Hannah L. ;

Murin, Charles D. ;

Li, Wen ;

Sok, Devin ;

Souders, Colby A. ;

Piper, Ashley E. ;

Goff, Arthur ;

Shamblin, Joshua D. ;

Wollen, Suzanne E. ;

Sprague, Thomas R. ;

Fusco, Marnie L. ;

Pommert, Kathleen B. J. ;

Cavacini, Lisa A. ;

Smith, Heidi L. ;

Klempner, Mark ;

Reimann, Keith A. ;

Krauland, Eric ;

Gerngross, Tillman U. ;

Wittrup, Karl D. ;

Saphire, Erica Ollmann ;

Burton, Dennis R. ;

Glass, Pamela J. ;

Ward, Andrew B. ;

Walker, Laura M. .

SCIENCE, 2016, 351 (6277) :1078-1083

[6] Monoclonal antibodies for prophylactic and therapeutic use against viral infections [J].

Both, Leonard ;

Banyard, Ashley C. ;

van Dolleweerd, Craig ;

Wright, Edward ;

Ma, Julian K-C ;

Fooks, Anthony R. .

VACCINE, 2013, 31 (12) :1553-1559

[7] Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity [J].

Bournazos, Stylianos ;

Klein, Florian ;

Pietzsch, John ;

Seaman, Michael S. ;

Nussenzweig, Michel C. ;

Ravetch, Jeffrey V. .

CELL, 2014, 158 (06) :1243-1253

[8] Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage [J].

Bowley, D. R. ;

Labrijn, A. F. ;

Zwick, M. B. ;

Burton, D. R. .

PROTEIN ENGINEERING DESIGN & SELECTION, 2007, 20 (02) :81-90

[9] Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections [J].

Bregenholt, Soren ;

Jensen, Allan ;

Lantto, Johan ;

Hyldig, Sara ;

Haurum, John S. .

CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (16) :2007-2015

[10] Therapeutic antibodies for human diseases at the dawn of the twenty-first century [J].

Brekke, OH ;

Sandlie, I .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (01) :52-62

← 1 2 3 4 5 6 7 8 9 10 →